Headquartered in Durham, NC Fiscal year ends March NASDAQ: IMVT immunovant.com
Immunovant, Inc. is a clinical-stage immunology company developing targeted anti-FcRn therapies for autoimmune diseases. It is a majority-owned subsidiary of Roivant (Nasdaq: ROIV).
Its business depends heavily on its lead candidate, IMVT-1402, which is in development across several autoimmune indications:
- **Difficult-to-treat rheumatoid arthritis:** the 600 mg dose met its primary endpoint in a potentially registrational trial, and FDA discussions are planned.
- **Graves' disease and myasthenia gravis:** topline data from potentially registrational trials are expected in calendar 2027.
- **Chronic inflammatory demyelinating polyneuropathy:** data are expected in 2028.
- **Sjögren's disease:** a fully enrolled Phase 2 trial is ongoing, but further development is unlikely.
The company is winding down clinical trials of its earlier anti-FcRn antibody, batoclimab. It has no product revenue and funds operations from its cash balance, which it says provides runway to a potential commercial launch of IMVT-1402 in Graves' disease. Updated
IMVT-1402 at 600 mg hit its primary endpoint in difficult-to-treat rheumatoid arthritis, with 92.5% of patients maintaining ACR20 response, and FDA talks on a registrational path come later this year. The 300 mg dose failed to separate from placebo and secondary endpoints missed significance, so the agency meeting decides how much of that $6.3 billion valuation holds.
Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying recently.
Immunovant, Inc. is a clinical-stage immunology company developing targeted anti-FcRn therapies for autoimmune diseases. It is a majority-owned subsidiary of Roivant (Nasdaq: ROIV).
24/7 Wall St.'s 12-month price target for IMVT is $58.55, rated Buy. The Wall Street consensus target is $48.31. IMVT price prediction →
